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Abstract
We address the challenge of detecting the contribution of noncoding mutations to disease with a 
deep-learning-based framework that predicts specific regulatory effects and the deleterious impact 
of genetic variants. Applying this framework to 1,790 Autism Spectrum Disorder (ASD) simplex 
families reveals disease causality of noncoding mutations: ASD probands harbor both 
transcriptional and post-transcriptional regulation-disrupting de novo mutations of significantly 
higher functional impact than unaffected siblings. Further analysis suggests involvement of 
noncoding mutations in synaptic transmission and neuronal development, and taken together with 
prior studies reveal a convergent genetic landscape of coding and noncoding mutations in ASD. 
We demonstrate that sequences carrying prioritized proband mutations possess allele-specific 
regulatory activity, and highlight a link between noncoding mutations and IQ heterogeneity in 
ASD probands. Our predictive genomics framework illuminates the role of noncoding mutations 
in ASD, prioritizes high impact mutations for further study, and is broadly applicable to complex 
human diseases.
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Introduction
Great progress has been made in the past decade in understanding autism spectrum disorder 
(ASD) genetics, establishing de novo mutations, including copy number variants (CNVs) 
and point mutations that likely disrupt protein coding genes, as important causes of ASD1,2. 
Yet all known ASD-associated genes together explain a small fraction of new cases, and it is 
estimated that overall de novo protein coding mutations, including CNVs, contribute to no 
more than 30% of simplex ASD cases2,3. The vast majority of identified de novo mutations 
are located within intronic and intergenic regions, yet little is known regarding their 
contribution to the genetic architecture of ASD or in disease pathogenesis more generally.
A potential role for noncoding mutations in complex human diseases including ASD has 
long been speculated. Human regulatory regions show signs of negative selection4, 
suggesting mutations within these regions lead to deleterious effects, and studies of inherited 
common variants have shown enriched disease association in noncoding regions5. 
Furthermore, noncoding mutations affecting gene expression have been discovered to cause 
Mendelian diseases6 and shown to be enriched in cancer7. Expression dosage effects have 
also been suggested as underlying the link between CNVs and ASD8. Recently, parentally-
inherited structural noncoding variants have been linked to ASD9. Also, on a small cohort of 
ASD families, some trends with limited sets of mutations have been reported10–12. Likewise, 
despite the major role RNA-binding proteins (RBPs) play in post-transcriptional regulation, 
little is known of the pathogenic effect of noncoding mutations affecting RBPs outside of the 
canonical splice sites. Thus, noncoding mutations could be a cause of ASD, yet no 
conclusive connection of regulatory de novo noncoding mutations, either transcriptional or 
post-transcriptional, to ASD etiology has been established.
Recent developments make it possible to perform large-scale studies that reliably identify 
noncoding de novo mutations at whole genome scale. The Simons Simplex Collection (SSC) 
whole genome sequencing (WGS) data for 1,790 families differs from many previous large-
scale studies in design by including matched unaffected siblings3,13–16. These provide 
critical background controls for detecting excess of proband mutations, as it is otherwise 
hard to distinguish disease-relevant excess of mutations from irrelevant biological and 
technical variation, such as genetic background differences or artificial biases from 
sequencing, variant calling, and filtering procedures.
However, even with study designs using matched control individuals, detecting the de novo 
noncoding contribution is still challenging, and establishing the role of the vast noncoding 
space in the genetic basis of autism remains elusive. Two recent studies17,18 demonstrated 
that even when considering a wide variety of possible functional annotation categories (e.g. 
mutations in known regulatory sites, mutations at the location of known histone marks, 
mutations near ASD- or disease-relevant gene sets), no significant noncoding ASD-proband-
specific signal was observed, and that approach would require a very large cohort to detect 
signal17. This is consistent with the expectation that noncoding mutations, in contrast to 
loss-of-function coding mutations, can vary highly in functional impact, with potentially 
only a small fraction of variants having strong effect size. Thus, the challenge is to move 
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beyond simple mutation counts, which are susceptible to both statistical power challenges 
and confounding factors, such as the rise in mutation counts with parental age. This 
difficulty is shared in other psychiatric diseases with complex genetic bases, such as 
intellectual disabilities and schizophrenia. In fact, little is known about the contribution of 
noncoding rare variants or de novo mutations to human diseases beyond the less common 
cases with Mendelian inheritance patterns.
To address this challenge, we used a systematic approach (Fig. 1a) that reliably identifies 
impactful noncoding mutations, analogous to using the genetic codon code to distinguish 
non-synonymous from synonymous protein coding mutations. This enables comparison of 
mutational burden between probands and siblings not simply in terms of number of 
mutations, but in terms of their functional impact. Specifically, we used biochemical data 
demarcating DNA and RNA binding protein interactions to train and deploy a deep 
convolutional-neural-network-based framework that predicts the functional and disease 
impact of de novo mutations in the SSC, with models trained for DNA and RNA. Our 
framework estimates, with single nucleotide resolution, the quantitative impact of each 
variant on 2,002 specific transcriptional and 232 specific post-transcriptional regulatory 
features, including histone marks, transcription factors and RNA-binding protein (RBP) 
profiles.
Using this approach, we discovered, at both DNA and RNA regulation levels, a significantly 
(multiple-hypothesis corrected) elevated burden of disruptive transcriptional-regulatory 
disrupting (TRD) and RBP-regulatory disrupting (RRD) proband mutations in ASD, 
providing evidence for causality of noncoding regulatory de novo mutations in autism. 
Notably, the functional impact difference between proband and sibling mutations is 
significant when considering de novo mutations genome-wide, with elevated effect sizes 
observed around loss-of-function intolerant genes (ExAC19). We also identify specific 
pathways and tissues affected by these mutations, experimentally verify the differential 
regulatory effect of prioritized variants, and explore a link between the noncoding mutations 
and IQ in ASD. We provide an interactive interface to explore de novo mutation impact 
predictions for the biomedical research community at hb.flatironinstitute.org/ASDbrowser.
Results
Contribution of transcriptional and post-transcriptional regulatory mutations to ASD
Analysis of the noncoding mutation contribution to ASD is challenging due to the difficulty 
of assessing which noncoding mutations are functional, and further, which of those 
contribute to the disease phenotype. For predicting the regulatory impact of noncoding 
mutations, we constructed a deep convolutional network-based framework to directly model 
the functional impact of each mutation and provide a biochemical interpretation including 
the disruption of transcription factor binding and chromatin mark establishment at the DNA 
level and of RBP binding at the RNA level (Supplementary Fig. 1, 2). At the DNA level, the 
framework includes cell-type specific transcriptional regulatory effect models from over 
2,000 genome-wide histone marks, transcription factor binding and chromatin accessibility 
profiles (from ENCODE and Roadmap Epigenomics projects20,21), extending the deep 
learning-based method that we described previously10 with redesigned architecture (leading 
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to significantly improved performance, p=6.7×10−123, Wilcoxon rank-sum test, 
Supplementary Fig. 2). At the RNA level, our deep learning-based method was trained on 
the precise biochemical profiles of over 230 RBP-RNA interactions (derived from CLIP 
data); such data can identify a wide range of post-transcriptional regulatory binding sites, 
including those involved in RNA splicing, localization and stability22. At both 
transcriptional and post-transcriptional levels, our models are accurate and robust in whole 
chromosome holdout evaluations (Supplementary Fig. 1b). Our models utilize a large 
sequence context to provide single nucleotide resolution to our predictions, while also 
capturing dependencies and interactions between various biochemical factors (e.g. histone 
marks or RBPs). This approach is data-driven, does not rely on known sequence 
information, such as transcription factor binding motifs, and it can predict impact of any 
mutation regardless of whether it has been previously observed, which is essential for the 
analysis of ASD de novo mutations. Finally, to link the biochemical disruption caused by a 
variant with phenotypic impact, we trained a regularized linear model using a set of curated 
human disease regulatory noncoding mutations6 (HGMD) and rare variants from healthy 
individuals in the 1000 Genomes populations23 to generate a predicted disease impact score 
(DIS) for each autism mutation independently based on its predicted transcriptional and 
post-transcriptional regulatory effects.
With these approaches, we systematically assessed the functional impact of de novo 
mutations on regulatory factor binding and chromatin properties, using data derived from 
7,097 whole genomes from the SSC cohort with our framework (total 127,140 non-repeat 
region SNVs, Supplementary Table 1). When considering all de novo mutations, we 
observed a significantly higher functional impact in probands compared to unaffected 
siblings, independently at the transcriptional (p=9.4×10−3, one-side Wilcoxon rank-sum test 
for all; FDR=0.033, corrected for all mutation sets tested) and post-transcriptional 
(p=2.4×10−4, FDR=0.0049) levels (Fig. 1b, all variants). This analysis is sensitive enough to 
discover noncoding contribution even if a very small fraction of the noncoding mutations are 
impactful (see power analysis in Supplementary Fig. 3). Furthermore, our finding is robust 
and significant directly at the level of biochemical disruptions predicted by DNA and RNA 
deep learning models as well as with alternative DIS training sets (Supplementary Fig. 4–5) 
or with inclusion or exclusion of protein coding regions (Supplementary Fig. 6–7).
Werling et al.17 raised the challenge of detecting any significant proband-specific signal even 
with highly specific subsets of genes or genomic regions, and correspondingly emphasized 
the need for proper multiple hypothesis correction; this challenge was still not resolved by a 
larger ASD cohort in a follow-up study18. Notably, our result above does not rely on any 
selection of variant subsets (e.g. those near predicted ASD-associated genes), is significant 
even after multiple hypothesis correction, and, unlike the mutation counts, the predicted 
mutation effects are not correlated with parental age (Supplementary Fig. 8), a confounding 
factor of mutation count-based analysis.
To gain further insight into the ASD noncoding regulatory landscape, we conducted a 
comprehensive analysis, with full multiple hypothesis correction for all combinations of 14 
gene-sets previously used in Werling et al.17 and 10 genomic regions tested (e.g. TSS or 
exon proximal). When restricted to genomic regions of higher regulatory potential (i.e. near 
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TSS or alternatively spliced exons), we observed an increased dysregulation effect size (Fig. 
1b–c, all genes, TRD p=5.6×10−4, FDR=0.0056; RRD p=2.2×10−4, FDR=0.0048). Among 
gene sets, we observed an elevated proband burden of high effect mutations close to loss-of-
function (LoF) intolerant genes (pLI > 0.9 from ExAC, 3,230 genes, TRD p=2.6×10−3, 
FDR=0.013; RRD p=1.1×10−3, FDR=0.0078) (Fig. 1b–c, Supplementary Fig. 9), suggesting 
LoF intolerant genes are highly vulnerable to noncoding disruptive mutations in ASD. This 
is consistent with the enrichment of coding loss-of-function mutations among the LoF 
intolerant genes in the SSC cohort24, indicating ASD signal convergence of noncoding and 
coding de novo mutations. Furthermore, we also find convergent signal at both 
transcriptional and post-transcriptional levels, thus providing further evidence for the causal 
role of noncoding effects in ASD (full analysis p-values and FDRs are available in 
Supplementary Table 2). We observe these signals consistently across SSC cohort subsets 
that were sequenced in different phases (Supplementary Fig. 10).
Tissue specificity and functional landscape of noncoding ASD-associated de novo 
mutations
Although one of the hallmarks of autism is altered brain development, a comprehensive 
tissue association has not been established for de novo noncoding variants. To explore the 
proband-specific tissue signal, we systematically tested the variant effects for tissue-specific 
genes derived from all 53 GTEx tissues and cell types25. We observed a consistent 
significant proband-specific mutation effect associated with brain tissues, with brain regions 
constituting the top 11 ranked tissues (by difference in proband vs sibling noncoding 
mutation effect) (Fig. 2a, all with FDR < 0.05). This provides strong evidence that high 
impact variants from the noncoding genome of ASD probands likely disrupt brain-specific 
gene regulation, consistent with previous findings for protein coding mutations30.
We next investigated the underlying processes and pathways impacted by de novo noncoding 
mutations in ASD. Such analysis is challenging because in addition to the variability in 
functional impact of mutations, ASD probands appear highly heterogeneous in underlying 
causal genetic perturbations26 and single mutations could cause a widespread effect on 
downstream genes. Thus to detect genes and pathways relevant to the pathogenicity of ASD 
TRD and RRD mutations, we developed a network-based statistical approach, NDEA 
(Network-neighborhood Differential Enrichment Analysis) (Supplementary Fig. 11). We 
used a brain-specific functional network that probabilistically integrates a large compendium 
of public omics data (e.g. expression, PPI, motifs) to represent how likely two genes are to 
act together in a biological process27. When applied to ASD de novo mutations, the NDEA 
approach identifies genes whose functional network neighborhood is significantly enriched 
for genes with stronger predicted disease impact in proband mutations compared to sibling 
mutations (Supplementary Table 3).
Globally, NDEA enrichment analysis pointed to a proband-specific role for noncoding 
mutations in affecting neuronal development, including in synaptic transmission and 
chromatin regulation (Fig. 2b, Supplementary Table 4), consistent with processes previously 
associated with ASD based on protein coding variants2, 30. Genes with significant NDEA 
enrichment were specifically involved in neurogenesis and grouped into two functionally 
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coherent clusters with Louvain community detection algorithm (Fig. 2c, Supplementary 
Table 5). The synaptic cluster is enriched in ion channels and receptors involved in 
neurogenesis (p=5.6×10−38), synaptic signaling (p=4.8×10−35) and synapse organization 
(p=1.5×10−18), including previously known ASD-associated genes such as those involved in 
synapse organization SHANK2, NLGN2, NRXN2, synaptic signaling NTRK2 and NTRK3, 
ion channels CACNA1A/C/E/G, KCNQ2, and neurotransmission SYNGAP1, GABRB3, 
GRIA1, GRIN2A28. The synapse cluster is also significantly enriched for plasma membrane 
proteins (p=3.9×10−24). In contrast, the chromatin cluster, representing chromatin regulation 
related processes, displayed an overrepresentation of nucleoplasm (p=2.1×10−9) proteins, 
with diverse functional roles including covalent chromatin modification (p=2.5×10−9), 
chromatin organization (5.2×10−8) and regulation of neurogenesis (p=6.4×10−5). The 
chromatin cluster also includes many known ASD-associated genes such as chromatin 
remodeling protein CHD8, chromatin modifiers KMT2A, KDM6B, and Parkinson’s disease 
causal mutation gene PINK129 which is also associated with ASD28 (Supplementary Table 
3). Overall, our results demonstrate pathway-level TRD and RRD mutation burden and 
identify distinct network level hot spots for high impact de novo mutations.
Next, we examined the genetic landscape of ASD-associated de novo noncoding and coding 
mutations. Specifically, in addition to the network analysis of noncoding mutations at the 
transcriptional and post-transitional level, we also applied it to the de novo coding 
mutations2. We compared the gene-specific NDEA statistic of elevated proband-specific 
noncoding mutation effect burden to that of the coding mutations, finding a significant 
positive correlation for both TRD and RRD (p=0.004 and Pearson’s r = 0.39 for TRD, 
p=0.042 and Pearson’s r = 0.30 for RRD; two-sided permutation test). Moreover, by network 
analysis, TRD and RRD are themselves significantly correlated (p=0.034 two-sided 
permutation test). This demonstrates that coding and noncoding mutations affect overlapping 
processes and pathways, indicating a convergent genetic landscape, and highlights the 
potential of ASD gene discovery by combining coding and noncoding mutations.
Experimental study of ASD noncoding mutation effects on gene regulation
Our analysis identified new candidate noncoding disease mutations with potential impact on 
ASD through regulation of gene expression. In order to add further evidence to a set of high 
confidence causal mutations, we experimentally studied allele-specific effects of predicted 
high-impact mutations in cell-based assays. For TRD mutations, fifty nine genomic regions 
showed strong transcriptional activity with 96% proband variants (57 variants) showing 
robust differential activity (Fig. 3, Methods); demonstrating that our prioritized de novo 
TRD mutations do indeed lie in regions with transcriptional regulatory potential and the 
predicted effects translate to measurable allele-specific expression effects. Among these 
genes with the demonstrated strong differential activity mutations, NEUROG1 encodes an 
important regulator of initiation of neuronal differentiation and in the NDEA analysis had 
significant network neighborhood proband excess (p=8.5×10−4), and DLGAP2 encodes a 
guanylate kinase localized to the post-synaptic density in neurons. Mutations near HES1 and 
FEZF1 also carried significant differential effect on activator activities: neurogenin, HES, 
and FEZF family transcription factors act in concert during development, both receiving and 
sending inputs to Wnt and Notch signaling in the developing central nervous system and 
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interestingly, the gut, to control stem cell fate decisions30–34; and Wnt and Notch pathways 
have been previously associated with autism26,35. SDC2 encodes a synaptic syndecan 
protein involved in dendritic spine formation and synaptic maturation, and a structural 
variant near the 3’ end of the gene was reported in an autistic individual (reviewed in Saied-
Santiago, 201736). Thus, our method identified alleles of high predicted impact that do 
indeed show changes in transcriptional regulatory activity in cells. Since many autism genes 
are under strong evolutionary selection, only effects exerted through (more subtle) gene 
expression changes may be observable because complete loss of function mutations may be 
lethal. This implies that further study of the prioritized noncoding regulatory mutations 
should yield insights into the range of dysregulations associated with autism.
In addition, as a case study for prioritized RRD mutations, we experimentally validated the 
effect of an ASD proband de novo noncoding mutation laying outside of a canonical splice 
site that we predicted to disrupt splicing of SMEK1 (ExAC pLI=1.0; Supplementary Fig. 
12), Smek1 has previously been shown to regulate cortical neurogenesis through the Wnt 
signaling pathway37. For this mutation, we observed a >40% reduction in the inclusion of 
the exon for the ASD proband allele compared to the sibling allele in a minigene assay 
(Methods), in agreement with the high predicted RRD impact. This demonstrates the highly 
disruptive biochemical impact a non-splice site de novo mutation can have on RNA splicing.
The individual level clinical relevance of the noncoding de novo mutations
The majority of ASD probands in the SSC do not have a de novo LoF coding mutation1,2 
and noncoding mutations outnumber LoF coding mutations by over 500 fold18. While 
individual impact of noncoding mutations may vary, as a group noncoding mutations could 
have significant clinical impact. Indeed, we observed a significant increase in ASD risk for 
individuals with higher burden of impactful de novo mutations (Supplementary Fig. 9, mean 
DIS per individual, Wilcoxon rank sum test one-sided p=1.4×10−3), with 25% of the SSC 
ASD probands incurring an aggregate noncoding ASD risk of 1.2 (odds ratio).
Furthermore, the overall contribution of de novo noncoding mutations (explaining 4.3% of 
the SSC ASD cases) is comparable to that of loss-of-function coding mutations (5.4%) and 
to that of missense mutations (3.1%) (Supplementary Fig. 13). This analysis leverages the 
power of the quad simplex design of the SSC cohort, enabling the estimation of causal 
contribution of each mutation category by correcting for the background occurrence rate 
among unaffected siblings (see Methods). Thus, our results demonstrate that noncoding de 
novo mutations have clinical relevance, although not all ASD probands will have impactful 
noncoding mutations (even in aggregate), and future work will be required to characterize 
their clinical impact and relationship to phenotypes.
One interesting direction is in association of impacts of noncoding mutations to specific 
phenotypes, such as IQ heterogeneity among ASD probands. Intellectual disability is 
estimated to impact 40–60% of autistic children38, and ASD individuals can over-inherit 
common variants associated with education attainment39. For de novo noncoding mutations 
analyzed in this study, we observe a significant association between noncoding mutations 
and IQ in ASD individuals. Specifically, lower IQ ASD individuals have a higher burden of 
RRDs in intronic regions flanking alternatively spliced exons of ExAC LoF intolerant genes. 
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This provides genetic evidence that aberrant splicing can contribute to the phenotypic 
heterogeneity observed among ASD probands (Supplementary Fig. 14, p=1.5×10−3), and 
should be taken into account when projecting clinical outcomes.
Discussion
Even with great strides in understanding the causes of ASD by sequencing and phenotyping 
of multiple cohorts in the recent years, much of the genetic basis underlying autism remains 
undiscovered. While a number of coding variants have been associated with ASD, no 
systematic evidence of de novo noncoding effect has been observed. Here we present a novel 
deep-learning based approach for quantitatively assessing the impact of noncoding 
mutations on human disease. Our approach addresses the statistical challenge of detecting 
the contribution of noncoding mutations by predicting their specific effects on 
transcriptional and post-transcriptional levels. This approach is general and can be applied to 
study contributions of noncoding mutations to any complex disease or phenotype.
Here, we apply our strategy to ASD using the 1,790 whole genome sequenced families from 
the Simons Simplex Collection, and for the first time demonstrate significant proband-
specific signal in regulatory de novo noncoding space. Importantly, we independently detect 
this signal not only at the transcriptional level, but also find significant proband-specific 
RRD burden. Previously, there’s been limited evidence for disease contribution of mutations 
disrupting post-transcriptional mechanisms outside of the canonical splice sites. We 
demonstrate significant ASD disease association at the de novo mutation level for variants 
impacting a large collection of RBPs regulating post-transcriptional regulation. Overall, our 
results suggest that both transcriptional and posttranscriptional mechanisms play a 
significant role in ASD etiology and possibly other complex diseases.
Notably, our study reveals important biological convergences among genetic dysregulations 
associated with ASD. Our analyses of the disease impact of both DNA and RNA effect 
mutations point to similar sets of impacted genes and pathways, indicating that the effects of 
regulatory mutations are convergent. Furthermore, high-impact noncoding regions we find in 
ASD probands impact the same genes previously found to be impacted by ASD LoF coding 
mutations. This convergence provides support for the causal contribution of noncoding 
regulatory mutations to ASD etiology.
Our analyses also demonstrate the potential of predicting disease phenotypes from genetic 
information, including de novo noncoding mutations. We provide a resource for further 
research into understanding the mechanism of noncoding impact on ASD, including 
computationally prioritized TRD and RRD mutations with strong predicted regulatory 
effects, as well as potentially disease contributing ASD proband mutations with 
experimentally confirmed effects (Supplementary Table 1,6 and hb.flatironinstitute.org/
ASDbrowser). However, there remains much room for further progress in this important 
area. We expect continuing development of noncoding mutation effect prediction methods 
will further improve the power of WGS studies in discovering the biological mechanisms of 
noncoding mutation contribution to autism and other complex human diseases.
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Methods
De novo mutation calling and filtering
The Simons Simplex Collection WGS data was made available via Simons Foundation 
Autism Research Initiative (SFARI), and was processed to generate variant calls via the 
standard GATK pipeline. The Simons Simplex Collection WGS data can be requested 
through SFARI Base (https://www.sfari.org/resource/sfari-base/), with the condition that the 
use of the data is limited to projects related to advancing the field of autism and related 
neurodevelopmental disorder research (questions on SSC consents should be directed to 
collections@sfari.org). To call de novo single nucleotide substitutions, inherited mutations 
were removed, and candidate de novo mutations were selected from the GATK variant calls 
where the alleles were not present in parents and the parents were homozygous with the 
same allele. DNMFilter classifier was then used to score each candidate de novo mutation 
and a threshold of probability > 0.75 was applied for SSC phase1–2 and probability > 0.5 
cutoff for phase3 to obtain a comparable number of high-confidence DNM calls across 
phases.
The DNMFilter40 classifier was trained with an expanded training set combining the original 
training standards with the verified DNMs from the SSC pilot WGS studies for the initial 40 
SSC families. For final analysis, de novo mutation calls within the low complexity repeat 
regions from UCSC browser table RepeatMasker41 were removed. Also, DNMs appearing in 
multiple SSC families (i.e. non-singleton DNMs) or individuals with outlier numbers of 
mutations (> 3 standard deviation more than average) were excluded from the analysis.
Overall genome-wide, we detect 77.7 mutations per individual with Ti/Tv ratio 2.01 with 
95% CI [2.00, 2.03] (78.7 for probands with Ti/Tv = 2.02 [1.99, 2.04], 76.7 for siblings with 
Ti/Tv=2.01 [1.99, 2.03]), with no significant difference in mutation substitution patterns 
between proband and sibling (Supplementary Fig. 15). The WGS DNM calls were compared 
against exome sequencing de novo mutations calls and previously validated SSC de novo 
mutations42: 87.9% of the exome sequencing mutations calls and 90.3% of the validated 
mutations were rediscovered in our mutation calls.
Training of DNA transcriptional regulatory effects and RNA posttranscriptional effects 
models
For training the transcriptional regulatory effects model, training labels, such as histone 
marks, transcription factors, and DNase I profiles, were processed from uniformly processed 
ENCODE and Roadmap Epigenomics data releases. The training procedure is as described 
in Zhou and Troyanskaya21 with the following modifications. The model architecture was 
extended to double the number of convolution layers for increased model depth (see 
Supplementary Note 1 for details). Similar to our previous model21, all layers except for the 
last linear layer were shared across all biochemical features. Input features were expanded to 
include all of the released Roadmap Epigenomics histone marks and DNase I profiles, 
resulting in 2,002 total features (Supplementary Table 7) compared to 919 original features.
For training the post-transcriptional regulatory effects model, we utilized the DeepSEA 
network architecture and training procedure with RNA-binding protein (RBP) profiles as 
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training labels (full list of parameters used in model is in Supplementary Note 1). We 
uniformly processed RNA features composed of 231 CLIP binding profiles for 82 unique 
RBPs (ENCODE and previously published CLIP datasets) and a branchpoint mapping 
profile as input features (full list of experimental features listed in Supplementary Table 8). 
CLIP data processing followed our previously detailed pipeline43, all CLIP peaks with p-
value < 0.1 were used for training with an additional filter requirement of two-fold 
enrichment over input for ENCODE eCLIP data. In contrast to the DeepSEA, only 
transcribed genic regions were considered as training labels for the post-transcriptional 
regulatory effects model. Specifically, all gene regions defined by Ensembl (mouse build 80, 
human build 75) were split into 50nt bins in the transcribed strand sequence. For each 
sequence bin, RBP profiles that overlapped more than half were assigned a positive label for 
the corresponding RBP model. Negative labels for a given RBP model were assigned to 
sequence bins where other RBP’s non-overlapping peaks were observed. Note that our deep 
learning models, both transcriptional and post-transcriptional, do not use any mutation data 
for training, thus it can predict impacts for any mutation regardless of whether it has been 
previously observed.
Disease impact score prediction
We used curated disease regulatory mutations and rare variants from healthy individuals to 
train a model that prioritizes likely disease-impacting mutations based on the predicted 
transcriptional or post-transcriptional regulatory impacts of these mutations. As positive 
examples, we used 4,401 regulatory noncoding mutations curated in the Human Gene 
Mutation Database (HGMD) with mutation type “regulatory” (DM, DM?, DFP, DP and FP). 
For negative examples of background mutations, we used 999,668 rare variants that were 
only observed once within the healthy individuals from the 1000 Genomes project23. We 
also showed that using common variants with AF>0.01 and location within 100kb to positive 
as negatives leads to similar conclusions (Supplementary Fig. 5). Absolute predicted 
probability differences computed by the convolutional network transcriptional regulatory 
effects model (described above) were used as input features for each of the 2,002 
transcriptional regulatory features and for the 232 post-transcriptional regulatory features in 
the disease impact model. Input features were standardized to unit variance and zero mean 
before being used for training. We separately trained a L2 regularized logistic regression 
model for transcriptional effect model (lambda=10) and post-transcriptional effect model 
(lambda=10, using only genic region variant examples) with the xgboost package (https://
github.com/dmlc/xgboost). The positive and negative training samples were separately 
weighted according to the inverse of the number of samples to address the label imbalance. 
The predicted probabilities are z-transformed to have mean 0 and standard deviation 1 across 
all proband and sibling mutations.
Gene sets and resources
All gene sets used are from Werling et al.17. The 14 gene-sets include GENCODE protein 
coding genes, Antisense, lincRNAs, Pseudogenes, genes with loss-of-function intolerance 
(pLI) score > 0.9 from ExAC19, predicted ASD risk genes (FDR < 0.3) from Sanders et al.8, 
FMRP target genes44, Genes associated with developmental delay45,46 andCHD8 target 
genes47,48. For genes with expression specific to each 53 GTEx tissue, we used expression 
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table from GTEx v7 (gene median TPM per tissue)25, we selected genes for which 
expression in a given tissue was five times higher than the median expression across all 
tissues.
We determined the representative TSS for each gene based on FANTOM CAGE 
transcription initiation counts relative to GENCODE gene models. Specifically, a CAGE 
peak is associated to a GENCODE gene if it is within 1000bp from a GENCODE v24 
annotated transcription start site49,50. Peaks within 1000bp to rRNA, snRNA, snoRNA or 
tRNA genes were removed to avoid confusion. Next, we selected the most abundant CAGE 
peak for each gene, and took the TSS position reported for the CAGE peak as the selected 
representative TSS for the Gene. For genes with no CAGE peaks assigned, we kept the 
GENCODE annotated gene start position as the representative TSS. FANTOM CAGE peak 
abundance data were downloaded at http://fantom.gsc.riken.jp/5/datafiles/latest/extra/
CAGE_peaks/ and the CAGE read counts were aggregated over all FANTOM 5 tissue or cell 
types. GENCODE v24 annotation lifted to GRCh37 coordinates were downloaded from 
http://www.gencodegenes.org/releases/24lift37.html. All chromatin profiles used from 
ENCODE and Roadmap Epigenomics projects were listed in Supplementary Table 7. The 
HGMD mutations are from HGMD professional version 2018.1.
Human exons that are alternatively spliced (AS) were obtained from a recent study that has 
examined publicly available human RNA-seq data to annotate an extensive catalog of AS 
events51. Internal exon regions (both 5’SS & 3’SS flanking introns), upstream exon (5’SS 
flanking introns), and downstream terminal exon (3’SS flanking introns) were used for 
alternative exon definition types of cassette, mutually exclusive, tandem cassette exons. 
Terminal exon region was used for intron retention, alternative 3’ or 5’ exon AS exon types. 
All selected exon-flanking intronic regions were collapsed into a final set of genomic 
intervals used to subset SNVs that are located within alternative splicing exon region (200 or 
400nts from exon boundary), illustrated in Supplementary Fig. 16.
Network differential enrichment analysis (NDEA)
Brain-specific functional relationship networks integrate a wide-range of functional genomic 
data in a tissue-specific manner and predicted the probability of functional association 
between any pair of genes27. This network was filtered to only include edges with >0.01 
probability (above Bayesian prior) to reduce the impact of noisy low-confidence edges.
We use NDEA to test the differential (proband vs sibling) impact of mutations on each gene 
or gene set. Intuitively, this test generates a p-value that reflects the proband-specific impact 
of mutations on that gene or gene set, including through its network neighborhood. This also 
enables statistical assessment of which gene sets (e.g. pathways) are significantly more 
affected by proband mutations compared to sibling mutations. Technically, NDEA performs 
a weighted two-sample (proband vs sibling mutations) test, where the weight for each 
observation is defined based on network connectivity scores (to the gene or gene sets) and 
two samples are compared based on weighted averages. Each weight is a non-negative 
constant number that is used to specify the relative contribution of an observation to the test 
statistic. When all weights are the same, it reduces to regular two-sample t tests; when the 
weights are different, it adjusted the standard t statistic to use appropriate variance resulting 
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from weighting. Note, unlike some other forms of weighted t-test, the weights are not 
random variables and do not represent sample sizes. The assumptions of the NDEA test are 
analogous to those of the standard two-sample t test, including that samples in each set are 
i.i.d. and the weighted sample means are normally distributed.
For each gene i, the NDEA t statistic is computed by
ti = μPi
− μSi
/Si 
μPi
=
∑m ∈ PWi j m dm
∑m ∈ PWi j m
,  μSi
=
∑m ∈ SWi j m dm
∑m ∈ SWi j m
Si =  
VPi
NPi
+
VSi
NSi
VPi
=
Σm ∈ pwi j m dm − μPi
Σm ∈ pwi j m −
Σm ∈ pwi j m
2
Σm ∈ pwi j m
2
,VSi
=
Σm ∈ swi j m dm − μSi
Σm ∈ swi j m −
Σm ∈ swi j m
2
Σm ∈ swi j m
2
NPi
=
∑m ∈ PWi j m
2
∑m ∈ PWi j m
2 ,  NSi
=
∑m ∈ SWi j m
2
∑m ∈ SWi j m
2
, in which μPi
 and μSi
 are weighted averages of disease impact scores dm of all proband 
mutations p or all sibling mutations S. Wij(m) is the network edge score (interpreted as 
functional relationship probability) between gene i and gene j(m) divided by the number of 
proband (if m is a proband mutation) or sibling (if m is a sibling mutation) mutations gene 
j(m) associated to, where j(m) indicate the implicated gene of the mutation m. P and S are 
the set of all proband mutations and the set of all sibling mutations included in the analysis. 
VPi
 and VSi
  are the unbiased estimates of population variance of μPi
 and μSi
.  NPi
 and NSi
are the effective sample sizes of proband and sibling mutations after network-based 
weighting for gene i.
Under null hypothesis of the two groups having no difference, the above t statistic 
approximately follows a t-distribution with the following degree of freedom:
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2
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For testing significance difference between proband and sibling mutations, mutations within 
100kb of the representative TSS of all genes and all intronic mutations within 400bp to exon 
boundary were included in this analysis. RNA disease impact scores were used as the 
mutation score for intronic mutations within 400bp to exon boundary and DNA disease 
impact scores were used for other mutations.
For gene set level NDEA, we consider the gene set as a meta-node that contains all genes 
that are annotated to the gene set (e.g. GO term). Then, to any given gene the average of 
network edge scores for all genes in the meta-node is used as the weights. GO term 
annotations were pooled from human (EBI 5/9/2017), mouse (MGI 5/26/2017) and rat 
(RGD 4/8/2017). Query GO terms were obtained from the merged set of curated GO 
consortium52 slims from Generic, Synapse, ChEMBL, and supplemented by PANTHER53 
GO-slim and terms from NIGO54.
For network-based analysis of correlation between coding and noncoding TRD and RRD 
mutations, we first compute the NDEA t-statistic for every gene for all protein coding 
mutations from SSC exome sequencing study2,8, all SSC WGS noncoding mutations within 
100kb to a gene, and all SSC WGS genic noncoding mutations within 400bp to an exon, 
respectively. We then compute Pearson correlation across all resulting gene-specific t-
statistics between all three pairs of mutation types. For testing statistical significance of the 
correlation, we permuted proband and sibling labels for all mutations to compute the null 
distributions of correlations for each pair of mutation types. 1000 permutations were 
performed.
Network visualization and clustering
For network visualization, we computed a two-dimensional embedding with t-SNE55 by 
directly taking a distance matrix of all pairs of genes as the input. The distance matrix was 
computed as -log(probability) from the edge probability score matrix in the brain-specific 
functional relationship network. The Barnes-Hut t-SNE algorithm implemented in the Rtsne 
package was used for the computation. Louvain community clustering were performed on 
the subnetwork containing all protein coding genes with top 10% NDEA FDR.
Selection and cloning of Variant Allele Genomic Regions
All genomic sequences were retrieved from the hg19 human genome assembly. For 
experimental testing, we selected variants of high predicted disease impact scores larger than 
0 and included mutations near genes with evidence for ASD association, including those 
with coding LoF mutations (e.g. CACNA2D3) and a proximal structural variant (e.g. 
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SDC2). We did not explicitly select mutations based on proximity to TSSs, and the chosen 
mutations lie from between 7bp and 324kbp away from nearest TSS, with most variants 
lying farther than 5k from nearest TSS (Supplementary Table 6) For each allele (sibling or 
proband), we either cloned 230 nucleotides of genomic sequence amplified from proband 
lymphoblastoid cell lines or used FragmentGenes synthesized by Genewiz (Supplementary 
Table 6). In both cases, 15 nucleotide flanks on 5’ and 3’ ends matched each flank of the 
plasmid cloning sites (Supplementary Table 6. Synthesized fragments were cut with KpnI 
and BglII and cloned into pGL4.23 (Promega) cut with the same enzymes. PCR-amplified 
genomic DNA was cloned into pGL4.23 blunt-end cut with EcoRV and Eco53kI using 
GeneArtCloning method from Thermofisher Scientific. All constructs were verified by 
Sanger sequencing.
Luciferase Reporter Assays
Human neuroblastoma BE(2)-C cells were plated at 2×104 cells/well in 96-well plates and 
24 hours later were transfected with Lipofectamine 3000 (L3000–015, Thermofisher 
Scientific) together with 75ng of Promega pGL4.23 firefly luciferase vector containing the 
230nt of human genomic DNA from the loci of interest (Supplementary Table 6), and 4ng of 
pNL3.1 NanoLuc (shrimp luciferase) plasmid, for normalization of transfection conditions. 
42 hours after transfection, luminescence was detected with the Promega NanoGlo Dual 
Luciferase assay system (N1630) and BioTek Synergy plate reader. Four to six wells per 
variant were tested in each experiment. Variants were tested in at least two separate 
experiments. For each sequence tested, the ratio of firefly luminescence (ASD allele) to 
NanoLuc luminescence (transfection control) was calculated and then normalized to empty 
vector (pGL4.23 with no insert) on the same plate. Statistics were calculated from fold over 
empty vector values from each experiment and results from multiple replication experiments 
are combined with Fisher’s combined probability test. For presentation of the data, we 
normalized the fold over empty vector value of the proband allele to that of the sibling allele.
SMEK1 minigene assay
To construct the SMEK1 minigene, the genomic region was amplified with primers -- 
upstream exon + ~1,400nt intron and alternative exon, downstream exon + ~1,400nt intron, 
then cloned into pSG5 vector (Supplementary Table 6). The mutant minigene was 
constructed by assembling the PCR amplified vector backbone with synthetic gBlocks (IDT 
DNA) carrying the desired single base mutation (GRCh37:chr14:g.91932755G>A in RNA). 
Minigenes (2 μg) were transfected into SH-SY5Y cells and cells were harvested 48 h post-
transfection for immunoblotting or RT-qPCR following standard protocols. Three 
independent experiments were performed for statistical comparison.
Contribution of de novo mutations in ASD SSC
For LoF and missense coding mutations, we use annotations from Supplementary Table 1 of 
the SSC exome study Iossifov et al2. Out of total 2,508 probands, 331 ASD probands have at 
least one LoF coding mutation and 1,182 probands have at least one missense mutation. We 
estimate the expected number of background occurrences in probands using unaffected 
siblings occurrences adjusted by the overall proband/sibling ratio, resulting in 221.8 for LoF 
and 1105.0 for missense. The final estimated contribution was determined by the differential 
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between observed and background occurrences (e.g. for LoF, 331 minus 221.8 divided by 
2,508 probands, leading to an estimated contribution of 5.4%). For noncoding mutations, we 
observe 1,086 probands with mean DIS (mean of average DNA DIS and average RNA DIS) 
> 0, in comparison to a background occurrence of 1,009 per 1,781 individuals (unaffected 
siblings). The differential of 1,086 minus background 1,009, leads to an estimated 
contribution of 4.3%.
Statistical analysis
All details of the statistical tests are specified in the associated text or figure legends. The 
NDEA test is described in detail in the above “Network differential enrichment analysis 
(NDEA)” section.
Life Sciences Reporting Summary
Further information on experimental design is available in the Nature Research Reporting 
Summary linked to this article.
Code and data availability
The code is available from https://hb.flatironinstitute.org/asdbrowser/help. ASD WGS data 
can be obtained from the Simons Foundation Autism Research Initiative (SFARI). All 
variant predicted scores have been made available as supplementary material and an 
interactive web interface is available at https://hb.flatironinstitute.org/asdbrowser/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. The elevated noncoding regulatory mutation effect burden in Autism Spectrum Disorder.
a) Overall study design for deciphering the genome-wide de novo noncoding mutation 
effects contribution to ASD. 1,790 ASD simplex families’ whole genomes were sequenced 
to identify de novo mutations in the ASD probands and unaffected siblings. SNV de novo 
mutations were analyzed by their predicted transcriptional (chromatin and TFs) and post-
transcriptional (RNA-binding proteins) regulatory effect for comparison between probands 
and siblings.
b) ASD probands possess mutations with significantly higher predicted disease impact 
scores compared to their unaffected siblings. We observe significant burden of both 
transcriptional (DNA - all variants, n = 127,140) and post-transcriptional regulation (RNA - 
all transcribed variants, n = 77,149) altering mutations in probands. This proband excess is 
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stronger when restricted to mutation near all genes for DNA (n = 69,328) and near 
alternatively spliced exons for RNA (n = 4,871), and even stronger near ExAC LoF 
intolerant (DNA n = 14,873, RNA n = 1,355) genes. For analyses that include gene sets, 
variants were associated with the closest gene within 100kb of the representative TSS for 
transcriptional regulatory disruption (TRD) analysis. For RNA regulatory disruption (RRD) 
analysis, variants located in the introns within 400bp of flanking exons in alternative splicing 
regulatory regions were used. Wilcoxon rank sum test (one-sided) was used for computing 
the significance levels. All predicted disease impact scores were normalized by subtracting 
average predicted disease impact scores of sibling mutations for each comparison (mean DIS 
with the error bars indicate 95% CI). Every result is significant with multiple hypothesis 
correction (FDR < 0.05) and robust to inclusion or exclusion of protein coding region 
mutations (Supplementary Fig. 6).
c)Genomic variant set analysis of mutational burden for transcriptional- and 
posttranscriptional- disruptions. x-axis shows, for each gene set and distance cutoff, the 
effect size as defined as the difference between average DIS in probands and in siblings. 
Wilcoxon rank sum test (one-sided) was used for computing the significance levels. 
Significance level before and after correction for each category is listed in Supplementary 
Table 2. Categories shown in Fig. 1b are included in the annotation. All gene lists were 
obtained from Werling et al.17. Distance cutoffs for DNA are 10kb, 50kb, 100kb, 500kb, ∞ 
to TSS, and distance cutoffs for RNA are 200bp, 400bp, ∞ to all exons or to all alternatively 
spliced exons. DNA results shown in blue and RNA in orange; dot size corresponds to 
sample size (number of variants in a category); total sample size n = 127,140. Variant sets 
with >500 mutations are displayed. Full list of results are available in Supplementary Table 
2. Uncorrected p-values are shown in the y-axis and the dashed line indicates categories 
below FDR 0.05 threshold with the Benjamini-Hochberg method. Results are robust to 
inclusion or exclusion of protein coding region mutations (Supplementary Fig. 7).
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Fig. 2. Analysis of noncoding mutation effects converges on brain specific signals and 
neurodevelopmental processes.
a) Brain tissue-specific genes show strongest elevated proband-specific noncoding mutation 
effect burden. All 53 GTEx tissues are ranked by significance of increased proband mutation 
burden compared to unaffected siblings in tissue-specific genes (Methods). Uncorrected p-
values are shown in the y-axis and the dashed line indicates tissues below the FDR=0.05 
threshold corrected with the Benjamini-Hochberg method. Disease impact scores for all 
mutations within 100kb of representative TSSs (DNA) and intronic mutations within 400bp 
of exon boundaries (RNA) (n = 71,554) are used for the analysis.
b) Neuronal function and development related processes show significant excess of proband 
mutation disease impact scores by statistical test NDEA (full list in Supplementary Table 4, 
see also Methods). Analysis is conducted on the same mutation set as in (a). The top 
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processes (y-axis) and the p-values of proband excess (x-axis) are shown. Uncorrected p-
values are shown in the x-axis and all gene sets shown have FDR < 0.05.
c) Genes with significant network neighborhood excess of high-impact proband mutations 
form two functionally coherent clusters (see annotations for representative enriched gene 
sets in each cluster, full list is in Supplementary Table 5). Analysis is conducted on the same 
mutation set as in (a). The brain functional network is visualized by computing two-
dimensional embeddings with t-SNE (Methods). Genes, but not network edges, are shown 
for visualization clarity. Clustering was performed with Louvain community clustering. All 
genes in the two clusters shown are with FDR < 0.1.
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Fig. 3. Allele-specific transcriptional activity of ASD noncoding mutations.
Differential expression by proband or sibling alleles in a dual luciferase assay demonstrated 
that 57 predicted high TRD disease impact mutations fall in active regulatory elements and 
the mutations confer substantial changes to the regulatory potential of the sequence. Cells 
were transfected with pGL4.23-based expression plasmid containing 230nt of genomic 
region as well as a transfection control, and then luminescence was assayed 42h later 
(Methods). Y-axis shows the magnitude of transcription activation activity normalized to 
sibling allele. Significance levels were computed based on t-test and Fisher’s combined 
probability test (two-sided, stars indicate significance level *: p<0.05, **: p<0.01, ***: 
p<0.001, ****: p<0.0001; Methods). Sample sizes for all tests are in Supplementary Table 6. 
Central values of the box plot represent the median; the box extends from the 25th to the 
75th percentile; and whiskers extend to the maximum and minimum values no further than 
1.5 * IQR from the hinge (where IQR is the inter-quartile range, or distance between the first 
and third quartiles).
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